Page 154 - Read Online

Page 10 of 10 Banini et al. Hepatoma Res 2019;5:34 I http://dx.doi.org/10.20517/2394-5079.2019.30

55. Kuang SY, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection,
and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005;14:380-4.
56. Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular
carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004;110:374-9.
57. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by
electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 2005;14:2956-62.
58. Ikeda S, Tsigelny IF, Skjevik AA, Kono Y, Mendler M, et al. Next-generation sequencing of circulating tumor DNA reveals frequent
alterations in advanced hepatocellular carcinoma. Oncologist 2018;23:586-93.
59. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, et al. Detection and localization of surgically resectable cancers with a multi-analyte
blood test. Science 2018;359:926-30.
60. Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as
a liquid biopsy. Cell Mol Gastroenterol Hepatol 2015;1:516-34.
61. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, et al. Plasma Circulating cell-free DNA integrity as a promising biomarker for
diagnosis and surveillance in patients with hepatocellular carcinoma. J Cancer 2016;7:1798-803.
62. Pang JZ, Qin LX, Wang QQ, Ren N, Sun BS, et al. Loss of heterozygosity of plasma circulating DNA from hepatocellular carcinoma
patients and its clinical significance. Zhonghua Gan Zang Bing Za Zhi 2007;15:906-9.
63. Pang JZ, Qin LX, Ren N, Ye QH, Ying WD, et al. Microsatellite alterations of circulating DNA in the plasma of patients with
hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2006;86:1662-5.
64. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter
methylation in serum DNA. Clin Cancer Res 2007;13:2378-84.
65. Iyer P, Zekri AR, Hung CW, Schiefelbein E, Ismail K, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of
Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2010;88:107-11.
66. Iizuka N, Oka M, Sakaida I, Moribe T, Miura T, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of
epigenetic and classical protein markers. Clin Chim Acta 2011;412:152-8.
67. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and
prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011;91:702-7.
68. Sun FK, Fan YC, Zhao J, Zhang F, Gao S, et al. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig
Dis Sci 2013;58:1010-5.
69. Chang H, Yi B, Li L, Zhang HY, Sun F, et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease
patients. Exp Mol Pathol 2008;85:96-100.
70. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma
of patients with hepatocellular carcinoma. Liver Int 2005;25:266-72.
71. Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, et al. Gene expression and DNA methylation alterations in the
glycine N-methyltransferase gene in diet-induced nonalcoholic fatty liver disease-associated carcinogenesis. Toxicol Sci 2019; doi:
10.1093/toxsci/kfz110.
72. Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, et al. Serum LINE-1 hypomethylation as a potential
prognostic marker for hepatocellular carcinoma. Clin Chim Acta 2007;379:127-33.
73. Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, et al. Is serum level of methylated RASSF1A valuable in
diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 2012;13:111-5.
74. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of
hepatocellular carcinoma. Nat Mater 2017;16:1155-61.